API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.novartis.com/news/media-releases/novartis-announces-met-inhibitor-tabrecta-approved-japan-advanced-non-small-cell-lung-cancer-metex14
https://www.fiercepharma.com/marketing/novartis-leans-into-digital-for-mid-pandemic-lung-cancer-launch
https://www.raps.org/news-and-articles/news-articles/2020/5/notable-approvals-fda-approves-tabrecta-adds-indic
http://www.pharmafile.com/news/548156/fda-approval-tabrecta-metastatic-non-small-cell-lung-cancer-metex14
https://www.fiercepharma.com/pharma/novartis-beats-merck-kgaa-to-finish-line-targeted-lung-cancer-drug-capmatinib
https://endpts.com/novartis-lands-capmatinib-approval-giving-them-a-second-potential-blockbuster-from-incyte/
http://www.pharmafile.com/news/548156/fda-approval-tabrecta-metastatic-non-small-cell-lung-cancer-metex14
https://www.prnewswire.com/news-releases/novartis-announces-fda-approval-of-met-inhibitor-tabrecta-for-metastatic-non-small-cell-lung-cancer-with-metex14-301054213.html
https://www.fiercepharma.com/pharma/aacr-novartis-up-and-comer-capmatinib-successfully-fights-lung-cancer-brain
https://www.fiercepharma.com/pharma/embargoed-roche-s-tecentriq-added-to-cotellic-and-zelboraf-stalls-melanoma-progression